The Department of Labor and Employment (DOLE), the Department of Trade and Industry (DTI), and the Department of the Interior and Local Government (DILG) issued Joint Advisory No. 20-01, Series of 2020, or the “Implementation of New Policy Directions as the Country’s Policy Shifts from Total Risk Avoidance to Risk Management and on the Further Re-opening of the Economy” (Joint Advisory).
The Australian Government has released comprehensive terms of reference and an issues paper (“Issues Paper”) as part of its long-awaited review of the Australian Privacy Act 1988 (Cth) (“Privacy Act”). The review forms part of the government’s response in December 2019 to recommendations in the Australian Competition and Consumer Commission’s (ACCC) Digital Platforms Inquiry (“DPI Report”) to strengthen privacy laws in Australia. It marks the first of two papers seeking public input on the Privacy Act.
A number of recent merger assessments are now available on the VCCA’s website.
This update was published on 16 October 2020 as part of our quarterly newsletter, Asia Pacific Competition Highlights. Click here to access the full report, which covers the most notable antitrust developments across 11 Asia Pacific jurisdictions.
As COVID-19 rapidly spreads to every corner of the globe and is officially declared a pandemic, governments across the world are adopting emergency measures to fight against this extraordinary situation. Ultimately, all these measures are aimed at protecting the health and wellbeing of citizens. However, on the healthcare and life sciences front in particular, such measures range from intervention powers to guarantee adequate supplies of treatment and medical equipment, to the relaxation of deadlines and regulatory requirements to simplify administrative procedures wherever possible, so that competent authorities, manufacturers and other actors can focus on urgent priorities related to the COVID-19 crisis.
When a company is faced with an internal investigation, how many boards ask, How diverse is the investigation…
READ PUBLICATION Welcome to the November 2020 edition of Baker McKenzie’s International Trade Compliance Update. Here are the…
In brief On 22 October 2020, the FDA approved the anti-viral drug Veklury (remdesivir) for hospitalized COVID-19 patients, making it the first drug to receive approval for the treatment of COVID-19. Before approving this drug, the FDA issued an Emergency Use Authorization for the use of Veklury in COVID-19 treatment. We will…
Argentina is set to join with a new law the list of countries that have approved regulations to favor and accelerate the research, development and acquisition of Covid-19 vaccines. In a recent law approved by the Senate (which has yet to be promulgated by the President), broad and exceptional powers have been granted to the National Executive Power (the “Executive”) to negotiate the expedited purchase of such vaccines. The law authorizes to extend jurisdiction in favor of foreign judicial and arbitration tribunals and to agree to indemnities in favor of the entities that have developed or that sell the vaccines to the Executive. In addition, an exceptional procedure for the emergency regulatory approval of such vaccines was enacted.
After being the subject of 90 customer complaints from January 2019 to 31 August 2020, three beauty salons have signed Voluntary Compliance Agreements (“VCAs”) with the Consumers Association of Singapore (“CASE”) where they admit, and resolve to cease carrying out aggressive or misleading practices.
In brief Overview Zareenah Rasool, Candidate Attorney, Rui Lopes, Associate, and Darryl Bernstein, Partner and Head of the Healthcare and Lifesciences Industry Group at Baker McKenzie in Johannesburg, set out the infrastructure that is in place, and the processes that must be followed, for medicines such as the COVID-19 vaccine…